Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Cognitive development

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    233 result(s) found for: Cognitive development. Displaying page 1 of 12.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2013-004984-30 Sponsor Protocol Number: AD-4833/TOMM40_303 Start Date*: 2015-03-04
    Sponsor Name:Takeda Development Centre Europe Ltd
    Full Title: A Blinded Long-term Extension Study to Evaluate the Safety and Efficacy of Pioglitazone (AD-4833 Sustained Release 0.8 mg Daily) to Slow the Progression of Cognitive Decline in Subjects Who Have Co...
    Medical condition: Mild cognitive impairment due to Alzheimer’s disease
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004852 10009846 Cognitive impairment LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2012-003111-58 Sponsor Protocol Number: AD-4833/TOMM40_301 Start Date*: 2013-09-20
    Sponsor Name:Takeda Development Centre Europe Ltd
    Full Title: A Double Blind, Randomized, Placebo Controlled, Parallel Group Study to Simultaneously Qualify a Biomarker Algorithm for Prognosis of Risk of Developing Mild Cognitive Impairment due to Alzheimer’s...
    Medical condition: Mild cognitive impairment due to Alzheimer’s disease
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004852 10009846 Cognitive impairment LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: GB (Completed) IT (Prematurely Ended) DE (Completed)
    Trial results: View results
    EudraCT Number: 2011-004187-30 Sponsor Protocol Number: CO17730 Start Date*: 2011-12-14
    Sponsor Name:Avraham Pharmaceuticals Ltd.
    Full Title: A 36-month, multi-centre, randomized double-blind placebo-controlled study to evaluate the safety and efficacy of low dose Ladostigil in patients with Mild Cognitive Impairment (MCI)
    Medical condition: Patient with Mild Cognitive Impairment
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004852 10009846 Cognitive impairment LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2005-001281-13 Sponsor Protocol Number: KS-2004-06-SET Start Date*: 2005-11-15
    Sponsor Name:DSC Services, s.r.o.
    Full Title: Observational Study of Early Interferon beta 1-a Treatment in High Risk Subjects after CIS (SET Study)
    Medical condition: Clinically isolated syndrome suspected from demyelinating event (no better explanation for present symptoms)
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-004959-36 Sponsor Protocol Number: 446002504 Start Date*: 2020-09-30
    Sponsor Name:ZonMw
    Full Title: A proof of concept phase II study with the PDE-4 inhibitor roflumilast in patients with mild cognitive impairment (MCI).
    Medical condition: Mild Cognitive Impairment (MCI)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-004169-34 Sponsor Protocol Number: UoB1407 Start Date*: 2012-02-07
    Sponsor Name:University of Bristol
    Full Title: Effects of Varenicline and Cognitive Bias Modification on Neural Response to Smoking Cues
    Medical condition: Healthy volunteer trial: Neural responses to smoking cues Intended indication (Smoking cessation)
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2008-000046-31 Sponsor Protocol Number: Omega18-13-03 Start Date*: 2011-11-29
    Sponsor Name:The Sahlgrenska Center for Pediatric Ophtalmology Research
    Full Title: A randomised Intervention, Single-Center Study to Determine the Role of Fatty Acids in Serum in preventing Retinopathy of Prematurity
    Medical condition: Premature male/female infants, <28 gestational weeks at birth with risk of developing retinopathy of prematurity (ROP)
    Disease:
    Population Age: Preterm newborn infants, Under 18 Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-005298-22 Sponsor Protocol Number: Lu_AA21004_202 Start Date*: 2012-08-08
    Sponsor Name:Takeda Development Centre Europe Ltd.
    Full Title: A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Active-Referenced, Flexible Dose Study on the Efficacy of Lu AA21004 on Cognitive Dysfunction in Adult Subjects with Major Depressive...
    Medical condition: Cognitive Function in Major Depressive Disorder (MDD)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) FI (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2005-000979-18 Sponsor Protocol Number: AZ3100603 Start Date*: 2005-06-21
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: A phase IIa/b double-blind, randomised, placebo-controlled, linear trend design dose-ranging study to investigate the effects of 24 weeks of monotherapy with SB-742457 on cognition in subjects with...
    Medical condition: Alzheimer’s disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) SK (Completed) CZ (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2016-000222-19 Sponsor Protocol Number: H2020-PHC-18-2015-667224 Start Date*: 2017-08-02
    Sponsor Name:University Hospital Tuebingen
    Full Title: Effect of ALlopurinol in addition to hypothermia for hypoxic-ischemic Brain Injury on Neurocognitive Outcome – a blinded randomized placebo-controlled parallel group multicenter trial for superiori...
    Medical condition: Perinatal Asphyxia, hypoxic-ischemic brain injury
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10028923 Neonatal asphyxia PT
    20.0 10029205 - Nervous system disorders 10014633 Encephalopathy neonatal PT
    Population Age: Preterm newborn infants, Newborns, Under 18 Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) NL (Trial now transitioned) NO (Trial now transitioned) ES (Ongoing) FI (Trial now transitioned) EE (Trial now transitioned) AT (Trial now transitioned) BE (Trial now transitioned) PT (Prematurely Ended) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-002051-42 Sponsor Protocol Number: R119861 Start Date*: 2019-10-25
    Sponsor Name:University of Manchester
    Full Title: A phase I-II, study of autologous CD34+ haematopoietic stem cells transduced ex vivo with CD11b lentiviral vector encoding for human SGSH in patients with mucopolysaccharidosis type IIIA (MPS IIIA,...
    Medical condition: MPS IIIA, mucopolysaccharidosis type IIIA
    Disease: Version SOC Term Classification Code Term Level
    20.1 10010331 - Congenital, familial and genetic disorders 10028093 Mucopolysaccharidosis PT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2014-001411-39 Sponsor Protocol Number: ABT-002 Start Date*: 2018-09-04
    Sponsor Name:Abeona Therapeutics Inc
    Full Title: Phase I/II gene transfer clinical trial of rAAV9.CMV.hNAGLU for Mucopolysaccharidosis (MPS) IIIB
    Medical condition: MPS IIIB is a devastating lysosomal storage disease, caused by a N-α-acetylglucosaminidase (NAGLU) gene defect. Infants with MPS IIIB appear normal at birth, but the disease is relentlessly progre...
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) DE (Prematurely Ended) FR (Prematurely Ended) GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2006-000468-95 Sponsor Protocol Number: AZ3106242 Start Date*: 2006-06-16
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: A double-blind, randomised, placebo-controlled, parallel group study to investigate the effects of SB-742457, donepezil and placebo on cognition in subjects with mild to moderate Alzheimer's Disease
    Medical condition: Alzheimer's disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) AT (Completed) SK (Completed) EE (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2021-005552-11 Sponsor Protocol Number: LTS12869 Start Date*: 2022-03-07
    Sponsor Name:Genzyme Corporation
    Full Title: A Long-term Study to Evaluate Growth and Development Outcomes in Patients With Infantile-Onset Pompe Disease Who Are Receiving Alglucosidase Alfa.
    Medical condition: Pompe disease
    Disease: Version SOC Term Classification Code Term Level
    20.1 10010331 - Congenital, familial and genetic disorders 10053185 Glycogen storage disease type II PT
    Population Age: Newborns, Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2018-000195-15 Sponsor Protocol Number: P4-SAF-302 Start Date*: 2018-12-27
    Sponsor Name:Lysogene SA
    Full Title: An Open-Label, Single-Arm, Multicenter Study of Intracerebral Administration of Adeno-Associated Viral Vectors Serotype rh10 Carrying the Human N-sulfoglucosamine sulfohydrolase (SGSH) cDNA for the...
    Medical condition: Mucopolysaccharidosis Type IIIA
    Disease: Version SOC Term Classification Code Term Level
    20.1 10010331 - Congenital, familial and genetic disorders 10056890 Mucopolysaccharidosis III PT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: FR (Completed) GB (GB - no longer in EU/EEA) NL (Temporarily Halted) DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2014-005389-31 Sponsor Protocol Number: FBB-HUG-2014 Start Date*: 2015-02-18
    Sponsor Name:HôPITAUX UNIVERSITAIRES DE GENèVE
    Full Title: Incremental diagnostic value of Florbetaben Imaging vs other core biomarkers for Alzheimer Disease in patients with Mild Cognitive Impairment. An Investigator-Initiated Sponsored Study.
    Medical condition: Mild Cognitive Impairment
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004848 10050727 RI scan LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-003556-31 Sponsor Protocol Number: SHP-607-201 Start Date*: 2015-02-10
    Sponsor Name:Premacure AB, A Member of the Shire Group of Companies
    Full Title: Long-term Outcome of Children Enrolled in Study ROPP-2008-01 Previously Treated with rhIGF-1/rhIGFBP-3 for the Prevention of Retinopathy of Prematurity (ROP) or Who Received Standard Neonatal Care
    Medical condition: Retinopathy of Prematurity (ROP)
    Disease:
    Population Age: Newborns, Under 18 Gender: Male, Female
    Trial protocol: SE (Completed) GB (GB - no longer in EU/EEA) NL (Completed) PL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2020-002726-84 Sponsor Protocol Number: SHP607-203 Start Date*: Information not available in EudraCT
    Sponsor Name:Premacure AB
    Full Title: Long-Term Safety and Efficacy Outcomes Following Previously Administered Short-Term Treatment with SHP607 in Extremely Premature Infants
    Medical condition: Chronic Lung Disease
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004855 10066204 Chronic lung disease of prematurity LLT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-002527-21 Sponsor Protocol Number: AMYPAD-01 Start Date*: 2018-05-23
    Sponsor Name:University of Geneva
    Full Title: Multicentre, Open-label, Randomised Study to Assess the Diagnostic Value of Amyloid PET Imaging in Patients with Subjective Cognitive Decline Plus, Mild Cognitive Impairment, or Dementia Where Alzh...
    Medical condition: Alzheimer's disease Mild Cognitive Impairment Subjective Cognitive Decline Plus
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing) DE (Completed) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2022-000156-11 Sponsor Protocol Number: S65914 Start Date*: 2022-02-25
    Sponsor Name:KU Leuven
    Full Title: Oxytocin and the development of attachment: Looking beyond the expected?
    Medical condition: General healthy population children (ages 8 - 13 years old).
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: BE (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue May 06 12:06:54 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA